BMS, Janssen’s milvexian gets FDA fast track status for three indications
The fast track status for the investigational, oral factor XIa (FXIa) inhibitor (antithrombotic) has been granted in ischemic…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 May 23
The fast track status for the investigational, oral factor XIa (FXIa) inhibitor (antithrombotic) has been granted in ischemic…
26 May 23
The ground-breaking collaboration supports the aim of producing the first zero waste to landfill UEFA Finals by 2026
26 May 23
Working in conjunction with environmental NGO Delterra, these three organizations will join forces to impact 10 million people…
26 May 23
Continuous Artificial Intelligence (AI) and software updates will be provided by GE HealthCare’s Smart Subscription, a service to…
26 May 23
Largest Candy and Snack Trade Show in North America Heads to Indianapolis and Las Vegas
26 May 23
A.Menarini Diagnostics S.r.l. is pleased to announce the commercial launch of its PRIME MDx platform: a sample-to-result, all-in-one,…
26 May 23
IBSA, which has made innovation one of its pillars, partnered with InSilicoTrials with the objective of evaluating the…
25 May 23
Yuflyma is now approved to treat eight conditions, including juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, Crohn’s disease,…
25 May 23
Under the agreement, Advanz will be responsible for the registration and commercialisation of the candidates in Europe and…
25 May 23
Under the terms of the transaction, Pyxis Oncology expects to issue around 4.4 million shares of its common…